BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare I&I Disease Analysis: Psoriasis

May 13, 2020

Psoriasis is a chronic inflammatory skin disorder affecting around 2–3% of the world’s population. It is identified as thick scaling red plaques, resulting from an unusually high rate of skin cell growth. It usually involves the skin and nails, and leads to lesions which cause itching, stinging, and pain. While the main cause of psoriasis remains uncertain, several studies have reported that it is due to autoimmunity, genetic predisposition, and environmental factors. Additionally, psoriasis may be provoked by several triggers, including trauma, obesity, infection, systemic drugs, and stress.

While the psoriasis market will see downward pressure from the arrival of biosimilars of the key marketed anti-TNF brands, Enbrel and Humira, overall growth will be driven partly by the recent launch of a number of more targeted interleukin inhibitors. Despite the fact that newer, targeted biologics show higher efficacy in psoriasis over TNF-alpha inhibitors, the latter are often maintained as first-line treatment due to existing contracts that involve savings with a wide range of label expansions, beyond spondyloarthropathies.

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Psoriasis
Back to the top Back to the top